SGTX · Sigilon Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.90M | $4.86M | - | $4.25M | $2.88M | $3.17M | - | $1.95M | $2.70M | $3.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $7.45M | $7.78M | - | $8.28M | $11.88M | $11.62M | - | $16.64M | $12.45M | $13.27M |
| SG&A | $5.88M | $4.32M | - | $4.39M | $5.04M | $5.02M | - | $3.33M | $4.99M | $2.87M |
| Total Operating Expenses | $13.34M | $12.11M | - | $12.68M | $16.92M | $16.64M | - | $21.69M | $22.74M | $16.14M |
| D&A | $300.0K | $315.0K | - | $300.0K | $300.0K | $316.0K | - | $200.0K | $300.0K | $202.0K |
| Operating Income | ($7.43M) | ($7.25M) | - | ($8.42M) | ($14.04M) | ($13.48M) | - | ($19.74M) | ($13.32M) | ($12.68M) |
| Interest Expense | $310.0K | $611.0K | - | $606.0K | $543.0K | $491.0K | - | $293.0K | $196.0K | $208.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.51M) | ($7.38M) | - | ($8.67M) | ($14.35M) | ($13.86M) | - | ($13.19M) | ($20.44M) | ($12.73M) |
| EPS - Basic | ($3.00) | ($0.23) | - | ($0.27) | ($0.65) | ($0.43) | - | ($0.63) | - | - |
| EPS - Diluted | ($3.00) | ($0.23) | - | ($0.27) | ($0.44) | ($0.43) | - | ($0.63) | - | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.62M | $41.26M | $42.07M | $32.92M | $34.55M | $64.49M | $107.14M | $140.39M | $162.41M | $202.23M |
| Accounts Receivable | $4.50M | $3.16M | $2.17M | $23.0K | $23.0K | $62.0K | $59.0K | $27.0K | $178.0K | $177.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.11M | $1.33M | $936.0K | $1.41M | $1.05M | $2.04M | $2.34M | $3.23M | $4.66M | $2.01M |
| Current Assets | $44.87M | $64.65M | $74.41M | $80.63M | $92.17M | $109.65M | $126.39M | $144.03M | $166.27M | $183.06M |
| Total Assets | $55.56M | $76.59M | $87.28M | $94.62M | $107.42M | $126.17M | $144.37M | $163.80M | $186.12M | $225.05M |
| Current Liabilities | $25.25M | $28.99M | $30.99M | $30.55M | $33.32M | $37.05M | $34.89M | $40.87M | $44.39M | $47.02M |
| Long-term Debt | - | $10.41M | $12.02M | $13.62M | $15.22M | $16.81M | $18.41M | $20.00M | $20.00M | $20.00M |
| Total Liabilities | $28.11M | $43.29M | $48.14M | $50.21M | $55.61M | $61.58M | $67.21M | $70.49M | $75.05M | $78.89M |
| Stockholders' Equity | $27.45M | $33.29M | $39.14M | $44.41M | $51.81M | $64.59M | $77.16M | ($114.92M) | $111.07M | ($89.71M) |
| Retained Earnings | ($271.68M) | ($264.18M) | ($256.80M) | ($250.12M) | ($241.44M) | ($227.10M) | ($213.24M) | ($195.49M) | ($175.34M) | ($154.90M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($11.40M) | - | - | - | ($19.49M) | - | - | - | ($15.20M) |
| Investing Cash Flow | - | $12.24M | - | - | - | ($23.22M) | - | - | - | ($190.0K) |
| Financing Cash Flow | - | ($1.64M) | - | - | - | $48.0K | - | - | - | $27.07M |
| CapEx | - | $351.0K | - | - | - | $397.0K | - | - | - | $190.0K |
| Free Cash Flow | - | ($11.75M) | - | - | - | ($19.89M) | - | - | - | ($15.39M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -126.0% | -149.2% | - | -198.1% | -486.9% | -425.8% | - | -1013.8% | -492.6% | -365.8% |
| EBITDA margin | -120.9% | -142.7% | - | -191.0% | -476.4% | -415.8% | - | -1003.5% | -481.5% | -360.0% |
| Net margin | -127.2% | -151.9% | - | -203.9% | -497.6% | -437.9% | - | -677.7% | -755.8% | -367.4% |
| Free cash flow margin | - | -241.9% | - | - | - | -628.3% | - | - | - | -444.1% |
| FCF / Net income | - | 1.59 | - | - | - | 1.43 | - | - | - | 1.21 |
| R&D / Revenue | 126.3% | 160.2% | - | 194.7% | 412.0% | 367.1% | - | 854.9% | 460.5% | 383.0% |
| SG&A / Revenue | 99.7% | 89.0% | - | 103.4% | 174.9% | 158.7% | - | 171.2% | 184.6% | 82.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.5% | -9.6% | - | -9.2% | -13.4% | -11.0% | - | -8.1% | -11.0% | -5.7% |
| Return on equity | -27.3% | -22.2% | - | -19.5% | -27.7% | -21.5% | - | 11.5% | -18.4% | 14.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.78 | 2.23 | 2.40 | 2.64 | 2.77 | 2.96 | 3.62 | 3.52 | 3.75 | 3.89 |
| Quick ratio | 1.78 | 2.23 | 2.40 | 2.64 | 2.77 | 2.96 | 3.62 | 3.52 | 3.75 | 3.89 |
| Cash ratio | 0.78 | 1.42 | 1.36 | 1.08 | 1.04 | 1.74 | 3.07 | 3.44 | 3.66 | 4.30 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.31 | 0.31 | 0.31 | 0.29 | 0.26 | 0.24 | -0.17 | 0.18 | -0.22 |
| Debt / Assets | - | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 | 0.13 | 0.12 | 0.11 | 0.09 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -24.0x | -11.9x | - | -13.9x | -25.8x | -27.4x | - | -67.4x | -68.0x | -61.0x |
| Equity multiplier | 2.02 | 2.30 | 2.23 | 2.13 | 2.07 | 1.95 | 1.87 | -1.43 | 1.68 | -2.51 |
| Liabilities / Assets | 0.51 | 0.57 | 0.55 | 0.53 | 0.52 | 0.49 | 0.47 | 0.43 | 0.40 | 0.35 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.06 | - | 0.04 | 0.03 | 0.03 | - | 0.01 | 0.01 | 0.02 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 278d | 238d | - | 2d | 3d | 7d | - | 5d | 24d | 19d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 104.6% | 53.5% | - | 118.4% | 6.6% | -8.7% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 47.0% | 46.2% | - | 57.3% | -5.4% | -6.3% | - | - | - | - |
| Net income growth (YoY) | 47.7% | 46.8% | - | 34.3% | 29.8% | -8.8% | - | - | - | - |
| EPS growth (YoY) | -581.8% | 46.5% | - | 57.1% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 40.9% | - | - | - | -29.2% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -47.0% | -48.5% | -49.3% | - | -53.4% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sigilon Therapeutics against the 5 most active filers in the same SIC group.